Trichy Daily

Wet Age-Related Macular Degeneration Market to flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

 Breaking News
  • No posts were found

Wet Age-Related Macular Degeneration Market to flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

May 17
09:00 2022
Wet Age-Related Macular Degeneration Market to flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight
Wet Age-Related Macular Degeneration Market

DelveInsight’s “Wet Age-Related Macular Degeneration (Wet AMD) Market” report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.


Wet Age-Related Macular Degeneration (Wet AMD): An Overview

Age-related Macular Degeneration (AMD) is a leading cause of severe, irreversible blindness worldwide, profoundly affecting individuals’ quality of life. Wet AMD is a type of AMD characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid that may swell and damage the macula. Wet AMD is also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss.


Download Free Sample Report Now @


Some of the key highlights of the Wet AMD Market Report

  • In patients suffering from Wet Age-related Macular Degeneration, abnormal blood vessels grow under the retina and macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision resulting in rapid and severe vision loss.
  • According to available literature, females are affected more as compared to males, in the case of Wet AMD
  • As per a study titled “Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis” (2014), Between geographical regions, cases of early and any age-related macular degeneration were less prevalent in Asia than in Europe and North America (early:6.3% vs 14.3% and 12.8%; any: 6.9% vs 18.3% and 14.3%. The projected number of people with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040.
  • As per a study titled “Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future”, (2017), the prevalence of early AMD increased from 3.5% in those aged 55-59 years to 17.6% in those aged ≥85 years; for late AMD these figures were 0.1% and 9.8% respectively.

The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:

  • Total prevalent cases
  • Gender-specific cases
  • Age-specific cases


Get a sample copy of this report:


Wet Age-Related Macular Degeneration Treatment Market

Wet AMD has no cure even though an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients’ quality of life. According to the most recent AMD guidelines, the intravitreal administration of antivascular endothelial growth factor agents (anti-VEGF) constitutes the standard of care for Wet AMD patients due to the promising results provided by these therapies during clinical development. Angiogenesis inhibitors, the protein that promotes blood vessel growth, work by blocking VEGF activity. The most common and effective clinical treatment for Wet AMD is anti-VEGF therapy, a periodic intravitreal injection of a chemical called an anti-VEGF. Several VEGF therapies have been approved in the market for 7MM. These include Lucentis, Eylea, Macugen, and Boevu. Avastin is also used as an “off-label” drug.


Wet AMD Companies along with drugs

  • Faricimab: Roche
  • Conbercept: Chengdu Kanghong Biotech
  • KSI-301: Kodiak Sciences Inc.
  • OPT-302: Opthea Limited
  • AKST4290: Alkahest Inc.
  • Sunitinib Malate: Graybug Vision
  • PAN-90806: PanOptica, Inc.
  • Axitinib: Clearside Biomedical
  • HMR59: Hemera Biosciences
  • RBM-007: Ribomic USA Inc., and several others


Wet Age-Related Macular Degeneration Market Drivers

  • Drugs in Pipeline – Many products are in the pipeline like Faricimab, KSI-301, and OPT-302, which will help expand the market.
  • Diagnosis- Several diagnostic tests have been developed, including fluorescein angiography, indocyanine green angiography, and optical coherence tomography, to help in timely diagnosis.
  • Increased Prevalence – A huge patient pool allows any entrant access to a big market to realize substantial gains.
  • Genetic Therapy – Several genetic therapies are being developed, which can yield substantial gains for new entrants.
  • Extensive R&D and Personalized treatment


Visit for deep insights into the Wet Age-Related Macular Degeneration patient pool @


Wet Age-Related Macular Degeneration Market Barriers

  • Cost of Therapy – The high cost of therapy with gene therapy presents a considerable hurdle to access treatment.
  • Launch of Biosimilars – There is a lack of biomarkers to predict disease incidence, identify at-risk individuals, elucidate causative pathophysiological etiologies, and guide screening, monitoring, and treatment parameters to predict disease outcomes.
  • Future competition among similar drugs – Anti VEGF drugs will compete with each other, which could prove to be a barrier for new entrants.
  • Unmet needs associated with VEGF treatment – There are several unmet needs related to VEGF treatment, including loss of vision in almost 30% of patients getting treatment, and intravitreal injections requiring frequent and indefinite evaluations.


Request for More Info @


Table of content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis

4. Market Overview at a Glance

5. Disease Background and Overview

6. Patient Journey

7. Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Wet Age-Related Macular Degeneration (Wet AMD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Consult with our Business Expert @ 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Related Articles